Aclaris Therapeutics has secured an exclusive licence from Biosion for the global rights to two new antibodies, BSI-045B and ...

WAYNE, Pa., Nov. 18, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: ACRS) (the “Company” or “Aclaris”), a clinical-stage ...

Enhances Aclaris’ pipeline with complementary biologics portfolio -- Expands leadership team with addition of seasoned ...

Aclaris (ACRS) soared 60% Tuesday, the day after the company announced it was licensing two drug candidates, prompting ...

Under the agreement, Biosion will receive over $40 million cash as an upfront license fee and reimbursement for certain development costs and drug product materials. Biosion said it will receive 19.9% ...

In a report released yesterday, Christopher Raymond from Piper Sandler upgraded Aclaris Therapeutics (ACRS – Research Report) to a Buy, with a ...

BTIG analyst Julian Harrison upgraded the rating on Aclaris Therapeutics (ACRS – Research Report) to a Buy yesterday, setting a price target of ...

On Monday, Aclaris Therapeutics, Inc. (NASDAQ:ACRS) entered into an exclusive license agreement with Biosion Inc for ...

Leerink Partners has recently raised Aclaris Therapeutics Inc (ACRS) stock to Outperform rating, as announced on Today, according to Finviz. Earlier, on Today, Jefferies had raised the stock from a ...

Aclaris Therapeutics has a 12 month low of $0.77 and a 12 month high of $2.72. The stock has a market capitalization of ...

Aclaris Therapeutics ($ACRS) stock rose more than 46% on Tuesday after the clinical-stage biopharmaceutical company entered ...